Computer Billing Standard

Publication
Article
OncologyONCOLOGY Vol 14 No 10
Volume 14
Issue 10

Physicians will have to use the “ANSI ASC X12N” electronic transmission format whenever they do computerized billing.

Physicians will have to use the “ANSI ASC X12N” electronic transmission format whenever they do computerized billing. The theory is that by using a single format (ANSI is the American National Standards Institute) instead of any of the 400 or so different ones kicking around today that a health plan might mandate, life will be simpler for physicians, and practice costs will decline precipitously. Medical practices with annual receipts over $5 million must be ANSI-compliant by October 2002. Those under that ceiling have until October 2003.

Articles in this issue
Computer Technology Helps Radiologists Spot Overlooked Small Breast Cancers
New Awards Spotlight Courage of Cancer Survivors
Using the Body’s Anticancer Defenses to Guide and Improve Breast Cancer Treatment
Vaccine Studies Demonstrate Promise of Immunotherapy to Treat Breast Cancer and Prevent Recurrence
Children’s Art Project at M. D. Anderson Cancer Center
Settling on an Increased NCI Budget
Computer Billing Standard
Ligand Receives FDA Marketing Clearance for Bexarotene Gel
Mayo Clinic Study Shows Patients Uncertain About Cancer Risk Terms
Multidisciplinary Management of Pediatric Soft-Tissue Sarcoma
Follow-up Care for Cancer: Making the Benefits Equal the Cost
Commentary (Stenson): Indications for Selective Neck Dissection: When, How, and Why
Follow-up Care for Cancer: Making the Benefits Equal the Cost
Costs of Smoking Among Active-Duty US Air Force Personnel—United States, 1997
Multidisciplinary Management of Pediatric Soft-Tissue Sarcoma
Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Related Content
Maximizing Safe Resection in High-Grade Gliomas

Maximizing Safe Resection in High-Grade Gliomas

Ariana Pelosci
May 13th 2025
Article

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

"SurVaxM’s excellent safety profile and tolerability to date also help optimize quality of life for patients with this highly aggressive cancer, where additional treatment options are direly needed," according to Ajay Abad, MD, of Roswell Park Comprehensive Cancer Center.

Phase 2B Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue

Russ Conroy
May 12th 2025
Article

An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Ariana Pelosci
May 12th 2025
Article

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article